Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 17/20 | 1.00 |
| ▸ | TACR3 | P29371 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877264 | 1.00 | ADH5 (1.00) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL1516396 | 1.00 | ADH5 (1.00) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL876925 | 0.98 | ADH5 (0.96) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL876332 | 0.98 | ADH5 (0.96) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL876687 | 0.96 | ADH5 (0.93) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL876429 | 0.95 | ADH5 (0.91) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL876274 | 0.95 | ADH5 (0.91) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL877163 | 0.95 | ADH5 (0.91) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL877585 | 0.95 | ADH5 (0.91) | ADH5TACR3MEN1ALDH1A1KMT2A | |
| SCHEMBL877645 | 0.95 | ADH5 (0.90) | ADH5TACR3MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | claimed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| US-9067893-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | claimed |
| US-8906933-B2 | Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists | N30 PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | claimed |
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| US-8741915-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | claimed |
| EP-2618666-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130131093-A1 | Novel Dihydropyrimidin-2(1H)-One Compounds As Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | claimed |
| EP-2480086-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | claimed |
| WO-2012039718-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-03-29 | — | — | WO | claimed |
| WO-2011038204-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-03-31 | — | — | WO | claimed |
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2480086-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012039718-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011038204-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ADH5 103/4885TACR3 500/4885MEN1 3816/4885 |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ADH5 103/4885TACR3 500/4885MEN1 3816/4885 |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | ADH5 103/4885TACR3 500/4885MEN1 3816/4885 |
| US-20130131093-A1 | Novel Dihydropyrimidin-2(1H)-One Compounds As Neurokinin-3 Receptor Antagonists | TAC3, TACR2, TACR3 | ADH5 2365/4885TACR3 3/4885MEN1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.